The proof of principle has already been provided decades ago when amplifications of 17q in a subset of breast cancer genes were revealed to harbor ERBB2 amplifications and became the basis for effective therapies that have changed the outcomes of HER2-positive breast cancers [27,28]. This evidence concerns the gene ERBB2 and breast carcinoma.